(Q38711094)

5 September 2017

0 references

CD73-adenosine: a next-generation target in immuno-oncology (English)

1 reference

5 September 2017

David Allard

1

1 reference

5 September 2017

Bertrand Allard

2

1 reference

5 September 2017

Pierre-Olivier Gaudreau

3

1 reference

5 September 2017

Pavel Chrobak

4

1 reference

5 September 2017

John Stagg

5

1 reference

5 September 2017

publication date

25 January 2016

1 reference

5 September 2017

1 reference

5 September 2017

volume

8

1 reference

5 September 2017

issue

2

1 reference

5 September 2017

page(s)

145-163

1 reference

Cell stress increases ATP release in NLRP3 inflammasome-mediated autoinflammatory diseases, resulting in cytokine imbalance

5 September 2017

cites work

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.106

Nucleotides released by apoptotic cells act as a find-me signal to promote phagocytic clearance

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.106

The P2X7 receptor is a key modulator of aerobic glycolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.106

Immunity, inflammation and cancer: a leading role for adenosine

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.106

CD39 and CD73 in immunity and inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.106

Targeting CD73 and downstream adenosine receptor signaling in triple-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.106

Early prediction of persistent organ failure by soluble CD73 in patients with acute pancreatitis*.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.106

IFN-beta regulates CD73 and adenosine expression at the blood-brain barrier.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.106

Characterization of different molecular forms of 5'-nucleotidase in normal serum and in serum from cholestatic patients and bile-duct-ligated rats

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.106

High expression and activity of ecto-5'-nucleotidase/CD73 in the male murine reproductive tract

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.106

Biochemical and mass spectrometric characterization of soluble ecto-5'-nucleotidase from bull seminal plasma.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.106

Oncogenic G Protein GNAQ Induces Uveal Melanoma and Intravasation in Mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.106

Autoimmunity in CD73/Ecto-5'-nucleotidase deficient mice induces renal injury

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.106

Impairment of tubuloglomerular feedback regulation of GFR in ecto-5'-nucleotidase/CD73-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.106

Targeted disruption of cd73/ecto-5'-nucleotidase alters thromboregulation and augments vascular inflammatory response

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.106

Neutrophil-derived 5'-adenosine monophosphate promotes endothelial barrier function via CD73-mediated conversion to adenosine and endothelial A2B receptor activation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.106

Crucial role for ecto-5'-nucleotidase (CD73) in vascular leakage during hypoxia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.106

Ecto-5'-nucleotidase (CD73) regulation by hypoxia-inducible factor-1 mediates permeability changes in intestinal epithelia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.106

CD73 is required for efficient entry of lymphocytes into the central nervous system during experimental autoimmune encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.106

Cardioprotection by ecto-5'-nucleotidase (CD73) and A2B adenosine receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.106

Ecto-5'-nucleotidase (CD73) -mediated extracellular adenosine production plays a critical role in hepatic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.106

Transfer of the glycosylphosphatidylinositol-anchored 5'-nucleotidase CD73 from adiposomes into rat adipocytes stimulates lipid synthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.106

Adenosine receptor signaling in the brain immune system

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.106

Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.106

CD73-deficient mice have increased antitumor immunity and are resistant to experimental metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.106

NT5E mutations and arterial calcifications

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.106

NT5E mutations that cause human disease are associated with intracellular mistrafficking of NT5E protein

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.106

Juxta-articular joint-capsule mineralization in CD73 deficient mice: similarities to patients with NT5E mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.106

Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.106

A2A adenosine receptor protects tumors from antitumor T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.106

CD73: A Novel Target for Cancer Immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.106

CD73 has distinct roles in nonhematopoietic and hematopoietic cells to promote tumor growth in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.106

Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.106

Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.106

Blockade of A2A receptors potently suppresses the metastasis of CD73+ tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.106

Antimetastatic effects of blocking PD-1 and the adenosine A2A receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.106

Transcriptional control of adenosine signaling by hypoxia-inducible transcription factors during ischemic or inflammatory disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.106

Hostile, hypoxia-A2-adenosinergic tumor biology as the next barrier to overcome for tumor immunologists

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.106

CD73 is associated with poor prognosis in high-grade serous ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.106

CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.106

IL-2 therapy promotes suppressive ICOS+ Treg expansion in melanoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.106

Reducing CD73 expression by IL1β-Programmed Th17 cells improves immunotherapeutic control of tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.106

Adenosine and prostaglandin E2 cooperate in the suppression of immune responses mediated by adaptive regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.106

The effect of intravenous interferon-beta-1a (FP-1201) on lung CD73 expression and on acute respiratory distress syndrome mortality: an open-label study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.106

Anti-CD73 therapy impairs tumor angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.106

p73 engages A2B receptor signalling to prime cancer cells to chemotherapy-induced death

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.106

Adenosine-induced apoptosis in EL-4 thymoma cells is caspase-independent and mediated through a non-classical adenosine receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.106

A new, sensitive ecto-5'-nucleotidase assay for compound screening.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.106

Pattern of metastatic spread in triple-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.106

Prognosis and adjuvant treatment effects in selected breast cancer subtypes of very young women (<35 years) with operable breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.106

Antagonism of adenosine A2A receptor expressed by lung adenocarcinoma tumor cells and cancer associated fibroblasts inhibits their growth

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.106

Extracellular adenosine regulates naive T cell development and peripheral maintenance

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.106

Overexpression of CD73 in epithelial ovarian carcinoma is associated with better prognosis, lower stage, better differentiation and lower regulatory T cell infiltration

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.106

α,β-Methylene-ADP (AOPCP) Derivatives and Analogues: Development of Potent and Selective ecto-5'-Nucleotidase (CD73) Inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.106

Development of potent and selective inhibitors of ecto-5'-nucleotidase based on an anthraquinone scaffold

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.106

Identification of sulfonic acids as efficient ecto-5'-nucleotidase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.106

Ecto-5'-nucleotidase/CD73 inhibition by quercetin in the human U138MG glioma cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.106

Production and characterization of monoclonal antibodies to the glycosyl phosphatidylinositol-anchored lymphocyte differentiation antigen ecto-5'-nucleotidase (CD73)

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.106

Immunotherapeutic approaches in triple-negative breast cancer: latest research and clinical prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.106

Triple-negative breast cancer: clinical features and patterns of recurrence

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.106

Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.106

The prognostic contribution of clinical breast cancer subtype, age, and race among patients with breast cancer brain metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.106

Molecular portraits of human breast tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.106

Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.106

Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.106

Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.106

Therapeutic targets in triple negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.106

Combining phenotypic and proteomic approaches to identify membrane targets in a 'triple negative' breast cancer cell type

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.106

Anti-human CD73 monoclonal antibody inhibits metastasis formation in human breast cancer by inducing clustering and internalization of CD73 expressed on the surface of cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.106

Role of estrogen receptor in the regulation of ecto-5'-nucleotidase and adenosine in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.106

RNA interference of ecto-5'-nucleotidase (CD73) inhibits human breast cancer cell growth and invasion

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.106

RNAi-mediated CD73 suppression induces apoptosis and cell-cycle arrest in human breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.106

Differential impact of adenosine nucleotides released by osteocytes on breast cancer growth and bone metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.106

Adenosine inhibits tumor cell invasion via receptor-independent mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.106

Ecto-5'-nucleotidase (CD73) promotes tumor angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.106

Identification of a pharmacologically tractable Fra-1/ADORA2B axis promoting breast cancer metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.106

Adenosine A2B receptor blockade slows growth of bladder and breast tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.106

An adenosine-mediated signaling pathway suppresses prenylation of the GTPase Rap1B and promotes cell scattering

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.106

New markers for minimal residual disease detection in acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.106

CD73-generated extracellular adenosine in chronic lymphocytic leukemia creates local conditions counteracting drug-induced cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.106

Prognostic markers and their clinical applicability in chronic lymphocytic leukemia: where do we stand?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.106

The role of ecto-5'-nucleotidase/CD73 in glioma cell line proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.106

Synergy between the ectoenzymes CD39 and CD73 contributes to adenosinergic immunosuppression in human malignant gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.106

5'-ectonucleotidase mediates multiple-drug resistance in glioblastoma multiforme cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.106

Primary glioblastomas express mesenchymal stem-like properties

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.106

The HIF-2alpha dependent induction of PAP and adenosine synthesis regulates glioblastoma stem cell function through the A2B adenosine receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.106

Modulation of A1 and A2B adenosine receptor activity: a new strategy to sensitise glioblastoma stem cells to chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.106

A1 adenosine receptors in microglia control glioblastoma-host interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.106

Adenosine receptor signaling: a key to opening the blood-brain door

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.106

Adenosine receptor signaling modulates permeability of the blood-brain barrier.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.106

Chronic caffeine treatment attenuates experimental autoimmune encephalomyelitis induced by guinea pig spinal cord homogenates in Wistar rats

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.106

A1 adenosine receptor upregulation and activation attenuates neuroinflammation and demyelination in a model of multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.106

Extracellular adenosine signaling induces CX3CL1 expression in the brain to promote experimental autoimmune encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.106

Recruitment of beneficial M2 macrophages to injured spinal cord is orchestrated by remote brain choroid plexus

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.106

Human brain endothelial cells are responsive to adenosine receptor activation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.106

A2A Adenosine Receptor Regulates the Human Blood-Brain Barrier Permeability

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.106

Tissue-resident ecto-5' nucleotidase (CD73) regulates leukocyte trafficking in the ischemic brain

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.106

Genetic inactivation of the adenosine A(2A) receptor exacerbates brain damage in mice with experimental autoimmune encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.106

Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.106

CD73-deficient mice are resistant to carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.106

Myeloid expression of adenosine A2A receptor suppresses T and NK cell responses in the solid tumor microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.106

Immunological mechanisms of the antitumor effects of supplemental oxygenation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.106

Host A(2B) adenosine receptors promote carcinoma growth

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.106

Knockdown of oncogenic KRAS in non-small cell lung cancers suppresses tumor growth and sensitizes tumor cells to targeted therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.106

KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.106

EGFR gene copy number assessment from areas with highest EGFR expression predicts response to anti-EGFR therapy in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.106

Autophagy in non-small cell lung carcinogenesis: A positive regulator of antitumor immunosurveillance

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.106

Expression of ecto-5'-nucleotidase (eN, CD73) in cell lines from various stages of human melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.106

Ecto-5'-nucleotidase (eN, CD73) is coexpressed with metastasis promoting antigens in human melanoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.106

NT5E (CD73) is epigenetically regulated in malignant melanoma and associated with metastatic site specificity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.106

Altered purinergic signaling in CD73-deficient mice inhibits tumor progression

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.106

Growth and metastasis of B16-F10 melanoma cells is not critically dependent on host CD73 expression in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.106

Enhancement of tumor immunotherapy by deletion of the A2A adenosine receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.106

Inhibition of CD73 improves B cell-mediated anti-tumor immunity in a mouse model of melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.106

Blockade of A2b adenosine receptor reduces tumor growth and immune suppression mediated by myeloid-derived suppressor cells in a mouse model of melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.106

21 January 2018

Cancer statistics, 2009

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.106

Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.106

Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.106

Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.106

CD73 on tumor cells impairs antitumor T-cell responses: a novel mechanism of tumor-induced immune suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.106

Gene expression profile of ovarian serous papillary carcinomas: identification of metastasis-associated genes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.106

Impaired Th1 immunity in ovarian cancer patients is mediated by TNFR2+ Tregs within the tumor microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.106

Ectonucleotidases CD39 and CD73 on OvCA cells are potent adenosine-generating enzymes responsible for adenosine receptor 2A-dependent suppression of T cell function and NK cell cytotoxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.106

Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.106

Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.106

Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.106

Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.106

Overexpression of CD73 in prostate cancer is associated with lymph node metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.106

Expression of adenosine receptor subclasses in malignant and adjacent normal human prostate tissues.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.106

Extracellular adenosine induces apoptosis of human arterial smooth muscle cells via A(2b)-purinoceptor

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.106

Activation of A2b adenosine receptor regulates ovarian cancer cell growth: involvement of Bax/Bcl-2 and caspase-3.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.106

Extracellular adenosine sensing-a metabolic cell death priming mechanism downstream of p53.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.106

Potential prognostic biomarker CD73 regulates epidermal growth factor receptor expression in human breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.106

NT5E CpG island methylation is a favourable breast cancer biomarker

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.106

The expression and clinical significance of CD73 molecule in human rectal adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.106

High expression of CD73 as a poor prognostic biomarker in human colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.106

NT5E and FcGBP as key regulators of TGF-1-induced epithelial-mesenchymal transition (EMT) are associated with tumor progression and survival of patients with gallbladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.106

Expression and clinical significance of CD73 and hypoxia-inducible factor-1α in gastric carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.106

CD73 Predicts Favorable Prognosis in Patients with Nonmuscle-Invasive Urothelial Bladder Cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.106

Virtual Screening Identifies Novel Sulfonamide Inhibitors of ecto-5′-Nucleotidase

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.15.106

21 January 2018

Identifiers

DOI

10.2217/IMT.15.106

1 reference

5 September 2017

1 reference